BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 15673656)

  • 21. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
    Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
    Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
    Mandel RJ; Spratt SK; Snyder RO; Leff SE
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14083-8. PubMed ID: 9391156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.
    Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P
    Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
    Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
    Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
    Lapchak PA; Miller PJ; Collins F; Jiao S
    Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease.
    Winkler C; Sauer H; Lee CS; Björklund A
    J Neurosci; 1996 Nov; 16(22):7206-15. PubMed ID: 8929429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
    Rosenblad C; Martinez-Serrano A; Björklund A
    Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
    Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
    Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal GDNF administration increases tyrosine hydroxylase phosphorylation in the rat striatum and substantia nigra.
    Salvatore MF; Zhang JL; Large DM; Wilson PE; Gash CR; Thomas TC; Haycock JW; Bing G; Stanford JA; Gash DM; Gerhardt GA
    J Neurochem; 2004 Jul; 90(1):245-54. PubMed ID: 15198683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
    Kirik D; Rosenblad C; Björklund A
    Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Lu XG; Gao Q; Geller AI
    Brain Res; 2005 Aug; 1052(2):119-29. PubMed ID: 16018990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GFR-α1 Expression in Substantia Nigra Increases Bilaterally Following Unilateral Striatal GDNF in Aged Rats and Attenuates Nigral Tyrosine Hydroxylase Loss Following 6-OHDA Nigrostriatal Lesion.
    Kasanga EA; Owens CL; Cantu MA; Richard AD; Davis RW; McDivitt LM; Blancher B; Pruett BS; Tan C; Gajewski A; Manfredsson FP; Nejtek VA; Salvatore MF
    ACS Chem Neurosci; 2019 Oct; 10(10):4237-4249. PubMed ID: 31538765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
    Rosenblad C; Kirik D; Björklund A
    Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery.
    Drinkut A; Tereshchenko Y; Schulz JB; Bähr M; Kügler S
    Mol Ther; 2012 Mar; 20(3):534-43. PubMed ID: 22086235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease.
    Ericson C; Georgievska B; Lundberg C
    Eur J Neurosci; 2005 Dec; 22(11):2755-64. PubMed ID: 16324109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomedicine. Combating Parkinson's disease--step three.
    Olson L
    Science; 2000 Oct; 290(5492):721-4. PubMed ID: 11184202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease.
    Duan D; Yang H; Zhang J; Zhang J; Xu Q
    Exp Brain Res; 2005 Mar; 161(3):316-24. PubMed ID: 15480595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.